Cambridge, Mass., February 5, 2018 — H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using its data science and precision chemistry product engine, today announced that company management will present an overview of the company at the 2018 BIO CEO & Investor Conference on Monday, February 12, 2018, at 9:45 a.m. EST at the New York Marriott Marquis in New York.
About H3 Biomedicine Inc.
H3 Biomedicine, a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, was established in 2011 as a subsidiary of Eisai’s U.S. pharmaceutical operation, Eisai Inc. H3 Biomedicine combines long-term vision with operational excellence, leveraging its collaboration with Eisai Co., Ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company. Using modern synthetic chemistry, chemical biology and human genetics, H3 Biomedicine seeks to bring the next generation of genomics-based cancer treatments to market with the goal of improving the lives of patients. For more information, please visit www.h3biomedicine.com.